文献速递传染病防控与疫情报告卫生政策与健康促进

单独分发纳洛酮或联合成瘾治疗及暴露前预防对注射吸毒者HIV预防的成本效果建模研究

Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study.
PubMed 文献 · Lancet Public Health · 2017-02-10

该决策分析马尔可夫模型模拟美国康涅狄格州注射吸毒者的阿片类药物过量、HIV新发感染及相关死亡,比较五种策略。与无额外干预相比,纳洛酮分发联合转介成瘾治疗具成本节约;联合暴露前预防与转介成瘾治疗在支付意愿阈值10万美元/QALY下ICER为95 337美元/QALY,具成本效果。

要点

  • 纳洛酮分发联合转介成瘾治疗与无额外干预相比具成本节约(效果更高且花费更少)。
  • 纳洛酮分发联合暴露前预防及转介成瘾治疗的ICER为每QALY 95 337美元。
  • 概率敏感性分析中,三联策略在37%的迭代中为最优策略,纳洛酮联合转介成瘾治疗在34%的迭代中为最优策略。

核心结论

  • 通过注射器服务项目分发纳洛酮与单独分发注射器相比具成本效果,但与转介成瘾治疗联合时与无额外服务相比具成本节约。
  • 联合纳洛酮分发、暴露前预防和转介成瘾治疗的策略为注射吸毒者带来更大健康获益且具成本效果。

研究设计与样本

  • 决策分析马尔可夫模型,模拟美国康涅狄格州注射吸毒者的阿片类药物过量、HIV发病率、过量相关死亡和HIV相关死亡。
  • 模型输入参数来自已发表文献,比较五种策略:无额外干预、纳洛酮分发、纳洛酮分发联合转介成瘾治疗、纳洛酮分发联合暴露前预防、纳洛酮分发联合转介成瘾治疗和暴露前预防。
  • 转介成瘾治疗定义为转介至阿片类药物成瘾治疗项目接受美沙酮治疗。
  • 对所有变量进行敏感性分析。

主要发现

  • 基础病例分析中,与无额外干预相比,纳洛酮分发策略的增量成本效果比(ICER)为每QALY 323美元。
  • 与无额外干预相比,纳洛酮分发联合转介成瘾治疗具成本节约(效果更高且花费更少)。
  • 在支付意愿阈值100 000美元/QALY下,最有效率的策略为纳洛酮分发联合转介成瘾治疗(成本节约),以及纳洛酮分发联合暴露前预防和转介成瘾治疗(ICER每QALY 95 337美元)。
  • 概率敏感性分析中,纳洛酮分发、暴露前预防和转介成瘾治疗三联策略在37%的迭代中为最优策略,纳洛酮分发联合转介成瘾治疗在34%的迭代中为最优策略。

关键数值与推荐

  • 与无额外干预相比,纳洛酮分发策略的ICER为每QALY 323美元。
  • 纳洛酮分发联合转介成瘾治疗与无额外干预相比为成本节约(效果更高且花费更少)。
  • 纳洛酮分发联合暴露前预防和转介成瘾治疗的ICER为每QALY 95 337美元(2015年美元),支付意愿阈值为100 000美元/QALY。
  • 概率敏感性分析中三联策略为最优策略的迭代比例为37%,纳洛酮联合转介成瘾治疗为最优策略的迭代比例为34%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the USA, an epidemic of opioid overdose deaths is occurring, many of which are from heroin. Combining naloxone distribution with linkage to addiction treatment or pre-exposure prophylaxis (PrEP) for HIV prevention through syringe service programmes has the potential to save lives and be cost-effective. We estimated the outcomes and cost-effectiveness of five alternative strategies: no additional intervention, naloxone distribution, naloxone distribution plus linkage to addiction treatment, naloxone distribution plus PrEP, and naloxone distribution plus linkage to addiction treatment and PrEP. METHODS: We developed a decision analytical Markov model to simulate opioid overdose, HIV incidence, overdose-related deaths, and HIV-related deaths in people who inject drugs in Connecticut, USA. Model input parameters were derived from published sources. We compared each strategy with no intervention, as well as simultaneously considering all strategies. Sensitivity analysis was done for all variables. Linkage to addiction treatment was referral to an opioid treatment programme for methadone. Endpoints were survival, life expectancy, quality-adjusted life-years (QALYs), number and percentage of overdose deaths averted, number of HIV-related deaths averted, total costs (in 2015 US$) associated with each strategy, and incremental cost per QALY gained. FINDINGS: In the base-case analysis, compared with no additional intervention, the naloxone distribution strategy yielded an incremental cost-effectiveness ratio (ICER) of $323 per QALY, and naloxone distribution plus linkage to addiction treatment was cost saving compared with no additional intervention (greater effectiveness and less expensive). The most efficient strategies (ie, those conferring the greatest health benefit for a particular budget) were naloxone distribution combined with linkage to addiction treatment (cost saving), and naloxone distribution combined with PrEP and linkage to addiction treatment (ICER $95 337 per QALY) at a willingness-to-pay threshold of $100 000. In probabilistic sensitivity analysis, the combination of naloxone distribution, PrEP, and linkage to addiction treatment was the optimal strategy in 37% of iterations and the combination of naloxone distribution and linkage to addiction treatment was the optimal strategy in 34% of iterations. INTERPRETATION: Naloxone distribution through syringe service programmes is cost-effective compared with syringe distribution alone, but when combined with linkage to addiction treatment is cost saving compared with no additional services. A strategy that combines naloxone distribution, PrEP, and linkage to addiction treatment results in greater health benefits in people who inject drugs and is also cost-effective. FUNDING: State of Connecticut Department of Public Health and the National Institute of Mental Health.

来源:Lancet Public Health,查看原文。版权归原作者所有。

引用

  1. Uyei J, Fiellin DA, Buchelli M, et al. Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study. Lancet Public Health. 2017. PMID: 29253386. doi:10.1016/S2468-2667(17)30006-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。